[AJS1] ASCO/JSMO合同シンポジウム　Tumor agnostic vs tumor specific approach toward clinical developments
【同通】【E】

[AJS-2] Regulatory considerations for drugs intended to treat patients agnostic of tumor type

^○Steven Lemery (Division of Oncology 3, Office of Oncologic Diseases, Center for Drug Evaluation and Research)